Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in Alnylam Pharmaceuticals in the 1st quarter worth about $275,000. Strs Ohio purchased a new position in Alnylam Pharmaceuticals during the first quarter worth approximately $7,781,000. GAMMA Investing LLC grew its holdings in Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after purchasing an additional 77 shares during the period. Finally, Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $243,000.